Adjuvant irinotecan-apatinib therapy for recurrent/metastatic gastric cancer after surgery: A real-world evaluation

Table 1 Baseline characteristics of the study groups, n (%)

Data	Control group (n = 60)	Research group (n = 64)	χ2/t	P value
Sex			0.719	0.396
Male	33 (55.00)	40 (62.50)
Female	27 (45.00)	24 (37.50)
Age (years)	54.62 ± 7.11	54.27 ± 7.73	0.262	0.794
Weight (kg)	61.50 ± 8.78	59.83 ± 9.38	1.022	0.309
Illness duration (months)	9.05 ± 1.66	9.17 ± 2.33	0.328	0.743
Clinical staging			0.440	0.507
II	20 (33.33)	25 (39.06)
III	40 (66.67)	39 (60.94)

Table 2 Comparative assessment of clinical response, n (%)

Response evaluation	Control group (n = 60)	Research group (n = 64)	χ2	P value
Complete response	11 (18.33)	17 (26.56)
Partial response	27 (45.00)	28 (43.75)
Stable disease	8 (13.33)	11 (17.19)
Progressive disease	14 (23.33)	8 (12.50)
Tumor control	46 (76.67)	56 (87.50)	2.490	0.115

Table 3 Comparative evaluation of treatment-emergent adverse events, n (%)

Adverse reactions	Control group (n = 60)	Research group (n = 64)	χ2	P value
Thrombocytopenia	17 (28.33)	10 (15.63)	2.936	0.087
Hemoglobin reduction	11 (18.33)	13 (20.31)	0.078	0.780
Nausea/vomiting	15 (25.00)	14 (21.88)	0.169	0.681
Myelosuppression	12 (20.00)	15 (23.44)	0.215	0.643

Table 4 Comparison of survival outcomes, n (%)

Survival rate	Control group (n = 60)	Research group (n = 64)	χ2	P value
6 months post operation	55 (91.67)	61 (95.31)	0.682	0.409
9 months post operation	47 (78.33)	56 (87.50)	1.850	0.174
12 months post operation	42 (70.00)	50 (78.13)	1.068	0.302

Table 5 Comparative life quality evaluation

Quality of life	Control group (n = 60)	Research group (n = 64)	t	P value
Material conditions (points)
Pre-treatment	64.05 ± 6.02	64.19 ± 7.51	0.114	0.909
Post-treatment	82.72 ± 7.06c	86.03 ± 6.32c	2.754	0.007
Mental well-being (points)
Pre-treatment	60.98 ± 5.91	62.80 ± 7.29	1.521	0.131
Post-treatment	82.87 ± 6.53c	88.66 ± 6.54c	4.930	< 0.001
Bodily function (points)
Pre-treatment	63.23 ± 5.00	64.27 ± 6.03	1.042	0.300
Post-treatment	84.57 ± 5.32c	89.33 ± 6.27c	4.544	< 0.001
Societal role (points)
Pre-treatment	66.25 ± 6.63	64.52 ± 6.38	1.481	0.141
Post-treatment	83.13 ± 6.77c	88.25 ± 5.66c	4.580	< 0.001

^cP < 0.001 vs pre-treatment within the same group.